Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report)'s share price shot up 4.8% during mid-day trading on Wednesday . The stock traded as high as $17.57 and last traded at $17.74. 62,867 shares were traded during trading, a decline of 68% from the average session volume of 193,498 shares. The stock had previously closed at $16.93.
Analysts Set New Price Targets
Separately, Wall Street Zen upgraded Pulse Biosciences to a "sell" rating in a report on Monday, March 31st.
View Our Latest Stock Report on Pulse Biosciences
Pulse Biosciences Stock Performance
The business has a 50-day moving average of $16.74 and a two-hundred day moving average of $17.97.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.25) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Pulse Biosciences
A number of large investors have recently made changes to their positions in PLSE. Rhumbline Advisers raised its stake in shares of Pulse Biosciences by 6.3% in the first quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock worth $440,000 after purchasing an additional 1,614 shares during the last quarter. Strs Ohio purchased a new stake in Pulse Biosciences in the first quarter valued at approximately $286,000. Jane Street Group LLC purchased a new position in Pulse Biosciences during the 1st quarter worth approximately $323,000. Panoramic Capital LLC lifted its stake in Pulse Biosciences by 8.5% during the 1st quarter. Panoramic Capital LLC now owns 52,723 shares of the company's stock valued at $848,000 after acquiring an additional 4,152 shares during the period. Finally, AlphaQuest LLC lifted its stake in Pulse Biosciences by 68.0% during the 1st quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock valued at $50,000 after acquiring an additional 1,261 shares during the period. 76.95% of the stock is owned by hedge funds and other institutional investors.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Read More
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
